文献速递先天性心脏病外科瓣膜外科

新型尺寸可调肺动脉瓣早期可行性研究一年结果

Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-07-31

Autus尺寸可调瓣膜(ASAV)是一种新型外科植入全合成可扩展肺动脉瓣,用于儿科患者。一年随访显示瓣膜功能完好,无器械相关不良事件。

要点

  • 1年随访90.9%无肺动脉反流,平均右室-肺动脉压差16±6 mmHg。
  • ASAV现已进入IDE关键性研究评估阶段。

核心结论

  • ASAV早期可行性研究一年结果显示瓣膜功能完好,无器械相关不良事件。

主要发现

  • 所有受试者植入时均进行尺寸调整,内径范围14 mm至20 mm(z评分-1至+1)。
  • 中位住院时间4天(范围3-5天),无死亡,100%受试者无器械相关不良事件,无血栓及心内膜炎发生。
  • 1年随访时10例(90.9%)无肺动脉反流,1例(8.1%)有微量肺动脉反流,平均右室-肺动脉压差16±6 mmHg。

临床怎么用

  • ASAV在儿科肺动脉瓣置换中展现一年期良好安全性和瓣膜功能,支持进一步关键性研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Autus Size-Adjustable Valve (ASAV) is a novel surgically implanted fully synthetic expandable pulmonary valve designed for pediatric patients. This first-in-human study evaluated initial device feasibility and safety. METHODS: This was a Food and Drug Administration-approved prospective, single-arm, multicenter Investigational Device Exemption Early Feasibility Study to evaluate safety and preliminary effectiveness of the ASAV in pediatric patients aged 18 months to 16 years who require pulmonary valve replacement. All potential subjects underwent review by a screening committee to determine eligibility. Subjects had pre- and postoperative evaluation via transthoracic echocardiography. One-year outcomes are reported. RESULTS: Eleven subjects (9 male) were enrolled at 3 centers. Median age at implant was 8.2 years (range, 2.7-13.9) years and body surface area ranged from 0.6 to 1.3 m2. The ASAV was size-adjusted at implant in all subjects, ranging from 14 mm to 20 mm internal diameter (z score -1 to +1). Median hospital length of stay was 4 (range, 3-5) days. There was no mortality, and 100% of subjects were free from device-related adverse events. No thrombus was observed. No subject developed endocarditis. At 1-year follow-up, 10 (90.9%) subjects had no pulmonary regurgitation (1 subject [8.1%] had trivial pulmonary regurgitation), and the mean right ventricle-pulmonary artery pressure gradient was 16 ± 6 mm Hg. CONCLUSIONS: One-year results of the novel ASAV Early Feasibility Study demonstrated intact valve function and no device-related adverse events. The ASAV is now under evaluation in an Investigational Device Exemption pivotal study.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Galantowicz ME, Stiver CA, Barry OM, et al. Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes. J Thorac Cardiovasc Surg. 2025. PMID: 40752778. doi:10.1016/j.jtcvs.2025.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。